Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research signal for this company.
Insider flow: Selling only — a count of disclosed transactions, not a rating or a recommendation.
Every open-market transaction disclosed for REPL in the synced window. Values are the insider's own, as filed.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-08-10 | Hill Emily Luisa | Chief Financial Officer | Open-market sell | 11,448 | 12.97 | $148,481 |
| 2026-08-10 | Xynos Konstantinos | Chief Medical Officer | Open-market sell | 11,447 | 12.97 | $148,468 |
| 2026-08-10 | Schwendenman Andrew | Chief Accounting Officer | Open-market sell | 7,632 | 12.97 | $98,987 |
Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.